U.S. Court of Appeals reversed a $1.2 billion damages award against Gilead Sciences in favor of Bristol-Myers. The three-judge panel concluded that the CAR-T patent, owned by Bristol-Myers, Juno Therapeutics and the Sloan Kettering Cancer Research Institute, was invalid. CAR-T is a method of treating cancer using the body's own immune system.